#phase-3-clinical-trials

[ follow ]
#mrna-influenza-vaccine #fda-refuse-to-file #regulatory-comparator-standard #retatrutide #glp-1glp-3
Public health
fromMedCity News
2 weeks ago

Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance - MedCity News

FDA refused to file Moderna's mRNA-1010 influenza vaccine application because the trial comparator did not reflect the U.S. standard of care.
Medicine
fromThe Atlantic
2 months ago

The Next Ozempic Is Already Being Sold Underground

Retatrutide, nicknamed "GLP-3," produced Phase 3 results showing average 71-pound (29%) weight loss—substantially exceeding semaglutide—yet remains unapproved.
[ Load more ]